Glypican-3 (GPC3), a carcinoembryonic antigen, is overexpressed in 72–81% of HCC cases, and is correlated with poor prognosis; therefore, it is an ideal target for HCC (3–7). The gene discussed is CEACAM5; the disease is hepatocellular carcinoma.